Together with LEO Pharma, we are building asset intelligence that picks up signals from the earliest discovery and preclinical stages through to late-stage development. By connecting company pipelines, clinical trials, publications, patents and news, we deliver comprehensive asset and company intelligence focused on the science and its validation, so promising innovation reaches patients faster.
Read LEO Pharma's LinkedIn post:
“📢 NEWS: We’re excited to announce a new partnership with AcademicLabs, an AI-powered scientific intelligence platform for early-stage research and innovation scouting.
🌍 AcademicLabs, based in Belgium, will give us deeper and faster insights into the innovation landscape in medical dermatology - spanning assets, mechanisms of action, modalities and development stages.
🤝 This 3-year collaboration aims to accelerate discoveries and help us identify and evaluate promising opportunities for LEO Pharma’s pipeline. By expanding visibility, including preclinical programmes, and combining diverse scientific data sources, AcademicLabs will unite previously siloed signals into 360° asset views. The result: faster, decision-ready insights that let us spot promising innovations, potential partners and in‑licensing opportunities earlier.
“This partnership adds to our internal machine-assisted scouting and evaluation engine developed in collaboration with LEO Pharma analytics experts. It helps us find and fast-track innovation that matters to patients, giving us earlier access to research and partnerships with the potential to change standards of care,” said Lars Erik Kristensen, VP, Head of External Innovation at LEO Pharma.
“At AcademicLabs, our mission is to turn scattered scientific signals into clear, decision-ready insights, especially in early R&D, where visibility is most limited. Partnering with LEO Pharma helps us accelerate that mission so innovation can reach patients faster,” said Arne Smolders, Founder and CEO of AcademicLabs.
🔎 We look forward to exploring new opportunities with AcademicLabs to bring additional high-potential innovation into our development pipeline.”
